TransCode Therapeutics Reports Positive Phase 1a Data for TTX-MC138

Filing content

TransCode Therapeutics announced updated Phase 1a clinical data for TTX-MC138, showing a 71.4% stable disease rate in patients with advanced solid tumors. The treatment was well-tolerated, and the company plans further clinical evaluation.